Schering Corporation

Merck Sharp + Dohme Corp.

Erin E Murphy

Terrill K McClanahan

Robert A Kastelein

Jason R Chan

Daniel M Gorman

Christi L Parham

Jeanine D Mattson

Theodore R Sana

Jeffery Grein

Kathleen M Smith

Chetan Savkoor

Naoko Arai

Hirokazu Kurata

Michael V Nebozhyn

Mark David Ayers

Andrey Loboda

Jared K Lunceford

Terrill K Mcclanahan

A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.

System and methods for deriving gene signature biomarkers of response to PD-1 antagonists

Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

Nucleic acids encoding TNF&#x3b3;

Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.

Method of treating skin inflammation

Nucleic acid encoding TNFx protein

Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17 and/or IL-23.

Method of treatment of skin inflammation

Method of evaluating inflammatory skin disorders using IL-17 and/or IL-19

Growing community of inventors

Palo Alto, CA, United States of America

Erin E Murphy